Signal Transduction and Targeted Therapy-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190341, encodeId=670911903415e, content=偏重的研究方向：信号通路 经验分享：请问这个杂志春节工作吗？春节前投的，已经两周了，一直under consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Sat Feb 05 16:26:19 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2098568, encodeId=d1e920985684d, content=要多久知道有没送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25485144056, createdName=14681389m42暂无昵称, createdTime=Fri Nov 04 20:17:37 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232517, encodeId=20d9123251ee6, content=送审的机会都不给，秒拒！越来越难投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519a5481432, createdName=ms2000001216044635, createdTime=Thu Jul 14 21:19:13 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917298, encodeId=1da791e2981d, content=审稿速度:1.0 | 投稿命中率:25.0 | 版面费用:2770.0 偏重的研究方向：肿瘤免疫;靶向药物;新冠肺炎 经验分享：编辑部效率较高，审稿人意见很犀利，达到子刊的水平。感觉发表的大部分是有新意和追热点的文章，看看影响力什么时候能赶上Cell Res吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=acb15453155, createdName=02hp, createdTime=Sun Jan 17 02:04:10 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=)]

2022-04-24 珍珍小坏

投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗

118 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190341, encodeId=670911903415e, content=偏重的研究方向：信号通路 经验分享：请问这个杂志春节工作吗？春节前投的，已经两周了，一直under consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Sat Feb 05 16:26:19 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2098568, encodeId=d1e920985684d, content=要多久知道有没送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25485144056, createdName=14681389m42暂无昵称, createdTime=Fri Nov 04 20:17:37 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232517, encodeId=20d9123251ee6, content=送审的机会都不给，秒拒！越来越难投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519a5481432, createdName=ms2000001216044635, createdTime=Thu Jul 14 21:19:13 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917298, encodeId=1da791e2981d, content=审稿速度:1.0 | 投稿命中率:25.0 | 版面费用:2770.0 偏重的研究方向：肿瘤免疫;靶向药物;新冠肺炎 经验分享：编辑部效率较高，审稿人意见很犀利，达到子刊的水平。感觉发表的大部分是有新意和追热点的文章，看看影响力什么时候能赶上Cell Res吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=acb15453155, createdName=02hp, createdTime=Sun Jan 17 02:04:10 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=)]

2022-02-05 ms7000000308199462

偏重的研究方向：信号通路
经验分享：请问这个杂志春节工作吗？春节前投的，已经两周了，一直under consideration.

98 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190341, encodeId=670911903415e, content=偏重的研究方向：信号通路 经验分享：请问这个杂志春节工作吗？春节前投的，已经两周了，一直under consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Sat Feb 05 16:26:19 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2098568, encodeId=d1e920985684d, content=要多久知道有没送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25485144056, createdName=14681389m42暂无昵称, createdTime=Fri Nov 04 20:17:37 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232517, encodeId=20d9123251ee6, content=送审的机会都不给，秒拒！越来越难投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519a5481432, createdName=ms2000001216044635, createdTime=Thu Jul 14 21:19:13 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917298, encodeId=1da791e2981d, content=审稿速度:1.0 | 投稿命中率:25.0 | 版面费用:2770.0 偏重的研究方向：肿瘤免疫;靶向药物;新冠肺炎 经验分享：编辑部效率较高，审稿人意见很犀利，达到子刊的水平。感觉发表的大部分是有新意和追热点的文章，看看影响力什么时候能赶上Cell Res吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=acb15453155, createdName=02hp, createdTime=Sun Jan 17 02:04:10 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=)]

2023-09-27 ms6000001571479804 来自湖北省

Manuscript Under Consideration一般多久呀

222 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190341, encodeId=670911903415e, content=偏重的研究方向：信号通路 经验分享：请问这个杂志春节工作吗？春节前投的，已经两周了，一直under consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Sat Feb 05 16:26:19 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2098568, encodeId=d1e920985684d, content=要多久知道有没送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25485144056, createdName=14681389m42暂无昵称, createdTime=Fri Nov 04 20:17:37 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232517, encodeId=20d9123251ee6, content=送审的机会都不给，秒拒！越来越难投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519a5481432, createdName=ms2000001216044635, createdTime=Thu Jul 14 21:19:13 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917298, encodeId=1da791e2981d, content=审稿速度:1.0 | 投稿命中率:25.0 | 版面费用:2770.0 偏重的研究方向：肿瘤免疫;靶向药物;新冠肺炎 经验分享：编辑部效率较高，审稿人意见很犀利，达到子刊的水平。感觉发表的大部分是有新意和追热点的文章，看看影响力什么时候能赶上Cell Res吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=acb15453155, createdName=02hp, createdTime=Sun Jan 17 02:04:10 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=)]

2022-11-04 14681389m42暂无昵称

要多久知道有没送审？

196 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190341, encodeId=670911903415e, content=偏重的研究方向：信号通路 经验分享：请问这个杂志春节工作吗？春节前投的，已经两周了，一直under consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Sat Feb 05 16:26:19 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2098568, encodeId=d1e920985684d, content=要多久知道有没送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25485144056, createdName=14681389m42暂无昵称, createdTime=Fri Nov 04 20:17:37 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232517, encodeId=20d9123251ee6, content=送审的机会都不给，秒拒！越来越难投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519a5481432, createdName=ms2000001216044635, createdTime=Thu Jul 14 21:19:13 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917298, encodeId=1da791e2981d, content=审稿速度:1.0 | 投稿命中率:25.0 | 版面费用:2770.0 偏重的研究方向：肿瘤免疫;靶向药物;新冠肺炎 经验分享：编辑部效率较高，审稿人意见很犀利，达到子刊的水平。感觉发表的大部分是有新意和追热点的文章，看看影响力什么时候能赶上Cell Res吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=acb15453155, createdName=02hp, createdTime=Sun Jan 17 02:04:10 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=)]

2022-07-14 ms2000001216044635

送审的机会都不给，秒拒！越来越难投！

180 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190341, encodeId=670911903415e, content=偏重的研究方向：信号通路 经验分享：请问这个杂志春节工作吗？春节前投的，已经两周了，一直under consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Sat Feb 05 16:26:19 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2098568, encodeId=d1e920985684d, content=要多久知道有没送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25485144056, createdName=14681389m42暂无昵称, createdTime=Fri Nov 04 20:17:37 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232517, encodeId=20d9123251ee6, content=送审的机会都不给，秒拒！越来越难投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519a5481432, createdName=ms2000001216044635, createdTime=Thu Jul 14 21:19:13 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917298, encodeId=1da791e2981d, content=审稿速度:1.0 | 投稿命中率:25.0 | 版面费用:2770.0 偏重的研究方向：肿瘤免疫;靶向药物;新冠肺炎 经验分享：编辑部效率较高，审稿人意见很犀利，达到子刊的水平。感觉发表的大部分是有新意和追热点的文章，看看影响力什么时候能赶上Cell Res吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=acb15453155, createdName=02hp, createdTime=Sun Jan 17 02:04:10 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=)]

2020-11-09 12034818m05(暂无昵称)

请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？

187 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190341, encodeId=670911903415e, content=偏重的研究方向：信号通路 经验分享：请问这个杂志春节工作吗？春节前投的，已经两周了，一直under consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Sat Feb 05 16:26:19 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2098568, encodeId=d1e920985684d, content=要多久知道有没送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25485144056, createdName=14681389m42暂无昵称, createdTime=Fri Nov 04 20:17:37 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232517, encodeId=20d9123251ee6, content=送审的机会都不给，秒拒！越来越难投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519a5481432, createdName=ms2000001216044635, createdTime=Thu Jul 14 21:19:13 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917298, encodeId=1da791e2981d, content=审稿速度:1.0 | 投稿命中率:25.0 | 版面费用:2770.0 偏重的研究方向：肿瘤免疫;靶向药物;新冠肺炎 经验分享：编辑部效率较高，审稿人意见很犀利，达到子刊的水平。感觉发表的大部分是有新意和追热点的文章，看看影响力什么时候能赶上Cell Res吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=acb15453155, createdName=02hp, createdTime=Sun Jan 17 02:04:10 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=)]

2021-01-17 02hp

审稿速度:1.0 | 投稿命中率:25.0 | 版面费用:2770.0
偏重的研究方向：肿瘤免疫;靶向药物;新冠肺炎
经验分享：编辑部效率较高，审稿人意见很犀利，达到子刊的水平。感觉发表的大部分是有新意和追热点的文章，看看影响力什么时候能赶上Cell Res吧。

206 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190341, encodeId=670911903415e, content=偏重的研究方向：信号通路 经验分享：请问这个杂志春节工作吗？春节前投的，已经两周了，一直under consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Sat Feb 05 16:26:19 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2098568, encodeId=d1e920985684d, content=要多久知道有没送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25485144056, createdName=14681389m42暂无昵称, createdTime=Fri Nov 04 20:17:37 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232517, encodeId=20d9123251ee6, content=送审的机会都不给，秒拒！越来越难投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519a5481432, createdName=ms2000001216044635, createdTime=Thu Jul 14 21:19:13 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917298, encodeId=1da791e2981d, content=审稿速度:1.0 | 投稿命中率:25.0 | 版面费用:2770.0 偏重的研究方向：肿瘤免疫;靶向药物;新冠肺炎 经验分享：编辑部效率较高，审稿人意见很犀利，达到子刊的水平。感觉发表的大部分是有新意和追热点的文章，看看影响力什么时候能赶上Cell Res吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=acb15453155, createdName=02hp, createdTime=Sun Jan 17 02:04:10 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=)]

2020-03-07 Smile S

您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表::
去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表:
去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下：
Waiting for Revision 3rd Jun 18 23:16:33
Decision Sent to Author 3rd Jun 18 23:16:33
Decision Made 3rd Jun 18 23:15:09
Manuscript Under Consideration 3rd Jun 18 23:14:28
Manuscript Under Consideration 14th May 18 03:25:03
Editor Assigned 14th May 18 02:09:17
Manuscript Received 14th May 18 02:09:16

sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16

174 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190341, encodeId=670911903415e, content=偏重的研究方向：信号通路 经验分享：请问这个杂志春节工作吗？春节前投的，已经两周了，一直under consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Sat Feb 05 16:26:19 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2098568, encodeId=d1e920985684d, content=要多久知道有没送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25485144056, createdName=14681389m42暂无昵称, createdTime=Fri Nov 04 20:17:37 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232517, encodeId=20d9123251ee6, content=送审的机会都不给，秒拒！越来越难投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519a5481432, createdName=ms2000001216044635, createdTime=Thu Jul 14 21:19:13 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917298, encodeId=1da791e2981d, content=审稿速度:1.0 | 投稿命中率:25.0 | 版面费用:2770.0 偏重的研究方向：肿瘤免疫;靶向药物;新冠肺炎 经验分享：编辑部效率较高，审稿人意见很犀利，达到子刊的水平。感觉发表的大部分是有新意和追热点的文章，看看影响力什么时候能赶上Cell Res吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=acb15453155, createdName=02hp, createdTime=Sun Jan 17 02:04:10 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=)]

2021-03-05 AtoZ

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了...

255 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190341, encodeId=670911903415e, content=偏重的研究方向：信号通路 经验分享：请问这个杂志春节工作吗？春节前投的，已经两周了，一直under consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Sat Feb 05 16:26:19 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2098568, encodeId=d1e920985684d, content=要多久知道有没送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25485144056, createdName=14681389m42暂无昵称, createdTime=Fri Nov 04 20:17:37 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232517, encodeId=20d9123251ee6, content=送审的机会都不给，秒拒！越来越难投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519a5481432, createdName=ms2000001216044635, createdTime=Thu Jul 14 21:19:13 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917298, encodeId=1da791e2981d, content=审稿速度:1.0 | 投稿命中率:25.0 | 版面费用:2770.0 偏重的研究方向：肿瘤免疫;靶向药物;新冠肺炎 经验分享：编辑部效率较高，审稿人意见很犀利，达到子刊的水平。感觉发表的大部分是有新意和追热点的文章，看看影响力什么时候能赶上Cell Res吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=acb15453155, createdName=02hp, createdTime=Sun Jan 17 02:04:10 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=)]

2021-09-29 ms6860193281304271

刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！

153 4

展开4条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务